Path to accelerated approval for Lexeo’s Friedreich ataxia gene therapy: Clinical Report

The week brought at least nine positive clinical readouts, but Lexeo’s was the only one that drove a sizable stock gain, after the biotech said feedback from FDA suggested a path to accelerated approval for its Friedreich ataxia gene therapy. 

Shares of Lexeo Therapeutics Inc. (NASDAQ:LXEO) rose 29% Tuesday, bringing its market cap to about $450 million, after an interim update from one of two Phase I/II trials of the AAV-based frataxin gene therapy LX2006 in Friedreich ataxia patients with cardiomyopathy. ...